HEALTH PRODUCTS REGULATORY AUTHORITY

Their core work

HPRA is Ireland's national regulatory authority responsible for the safety, quality, and efficacy of medicines and medical devices on the Irish market. In H2020 projects, they contribute regulatory expertise to EU-wide efforts on drug identification standards, medical device evidence frameworks, and regulatory science capacity building. Their participation bridges the gap between regulatory policy and practical implementation of cross-border health data systems, pharmacovigilance, and device safety standards.

What they specialise in

How they've shifted over time

HPRA's early H2020 involvement (2015–2016) centred on foundational medicine data harmonization through openMedicine. From 2019 onward, their focus expanded significantly into regulatory science training (STARS), large-scale medicine identification infrastructure (UNICOM), and medical device regulation (CORE-MD). The shift shows a move from basic data standards toward operational regulatory infrastructure and evidence-based frameworks for both drugs and devices.

HPRA is broadening from pharmaceutical data standards into medical device evidence and cross-border regulatory systems, positioning itself as a key EU regulatory implementation partner.

How they like to work

HPRA participates exclusively as a partner, never as coordinator — consistent with its role as a national regulatory authority contributing domain expertise rather than leading research agendas. With 74 unique partners across 25 countries, they operate in large, pan-European consortia typical of regulatory harmonization projects. This broad network indicates they are a trusted institutional partner that other organizations actively invite into consortia for regulatory credibility.

HPRA has collaborated with 74 distinct partners across 25 countries, reflecting the pan-European nature of regulatory harmonization work. Their network spans national regulatory agencies, the EMA ecosystem, universities, and health IT organizations across most EU member states.

What sets them apart

As Ireland's medicines and devices regulator, HPRA brings actual regulatory authority to EU projects — not just research expertise, but the perspective of an agency that implements and enforces the standards being developed. This makes them particularly valuable for projects that need to ensure research outputs will be accepted by regulators. Few project partners can offer both deep regulatory knowledge and the institutional mandate to act on it.

Highlights from their portfolio

• UNICOM
  Largest project (EUR 510K), focused on scaling global medicine identification standards (IDMP) with connections to EMA and cross-border eHealth networks.
• CORE-MD
  Addresses the critical gap in evidence generation for high-risk medical devices under the new EU Medical Device Regulation, spanning cardiology, orthopaedics, and diabetes devices.